CNS Drugs

, Volume 24, Issue 9, pp 741–753 | Cite as

The Association between Conventional Antidepressants and the Metabolic Syndrome

A Review of the Evidence and Clinical Implications
  • Roger S. McIntyre
  • Ka Young Park
  • Candy W. Y. Law
  • Farah Sultan
  • Amanda Adams
  • Maria Teresa Lourenco
  • Aaron K. S. Lo
  • Joanna K. Soczynska
  • Hanna Woldeyohannes
  • Mohammad Alsuwaidan
  • Jinju Yoon
  • Sidney H. Kennedy
Review Article


Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.


Metabolic Syndrome Major Depressive Disorder Bupropion Major Depressive Disorder Bulimia Nervosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr McIntyre has served on advisory boards for Astra Zeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, Schering-Plough and Merck; has served on speaker’s bureaux for Janssen-Ortho, Astra-Zeneca, Eli Lilly, Lundbeck, Biovail and Merck; has been involved in CME activities for Astra Zeneca, Bristol-Myers Squibb, France Foundation, I3CME, Solvay/Wyeth, Physicians’ Postgraduate Press, CME Outfitters, Optum Health, Schering-Plough, Merck and Eli Lilly; has received research grants from the Stanley Medical Research Institute, the National Alliance for Research on Schizophrenia and Depression (NARSAD), Eli Lilly, Janssen-Ortho, Shire, Astra-Zeneca and Pfizer; and has received travel funds from Bristol-Myers Squibb. Dr Kennedy has received grant funding and/or consultant fees from ANS, AstraZeneca, Biovail, Boehringer Ingelheim, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck Frosst, NARSAD, OMHF, OPGRS, Organon, Pfizer, Servier, the Stanley Foundation and Wyeth. Ms Soczynska has received honoraria from Organon and Wyeth. Dr Alsumaidan currently holds equity in sanofi-aventis. Drs Lo, Law, Lourenco, Park and Yoon, and Ms Woldeyohannes, Sultan and Adams, have no conflicts of interest that are directly relevant to the content of this review. No funding was received for the preparation of this review.

Supplementary material

40263_2012_24090741_MOESM1_ESM.pdf (271 kb)
Supplementary material, approximately 278 KB.


  1. 1.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3): 356–9PubMedCrossRefGoogle Scholar
  2. 2.
    Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006 Jul; 90(4): 573–91PubMedCrossRefGoogle Scholar
  3. 3.
    McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009 Feb; 9(1): 51–9PubMedCrossRefGoogle Scholar
  4. 4.
    Kooy FH. Hyperglycemia in mental disorders. Brain 1919; 42: 214–89CrossRefGoogle Scholar
  5. 5.
    Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001 Jun; 24(6): 1069–78PubMedCrossRefGoogle Scholar
  6. 6.
    Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 1993 Aug; 16(8): 1167–78PubMedCrossRefGoogle Scholar
  7. 7.
    Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000 Jul; 23(7): 934–42PubMedCrossRefGoogle Scholar
  8. 8.
    Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005 Apr; 118 Suppl. 2: 15S–22SPubMedGoogle Scholar
  9. 9.
    Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006 Sep; 67(9): 1422–7PubMedCrossRefGoogle Scholar
  10. 10.
    McCaffery JM, Niaura R, Todaro JF, et al. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study. Psychosom Med 2003 May; 65(3): 490–7PubMedCrossRefGoogle Scholar
  11. 11.
    McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry 2007 Oct; 19(4): 257–64PubMedCrossRefGoogle Scholar
  12. 12.
    Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6(4): 152–8PubMedCrossRefGoogle Scholar
  13. 13.
    Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. Depress Anxiety 2008; 25(8): 661–9PubMedCrossRefGoogle Scholar
  14. 14.
    Weber-Hamann B, Werner M, Hentschel F, et al. Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology 2006 Apr; 31(3): 347–54PubMedCrossRefGoogle Scholar
  15. 15.
    Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-Year follow-up study. J Clin Psychiatry 2008 Feb; 69(2): 178–82PubMedCrossRefGoogle Scholar
  16. 16.
    Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007 Dec; 29(4): 330–6PubMedCrossRefGoogle Scholar
  17. 17.
    Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996 Sep; 19(9): 920–6PubMedCrossRefGoogle Scholar
  18. 18.
    Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002 Dec; 51(12): 1573–7PubMedCrossRefGoogle Scholar
  19. 19.
    McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002; 63 Suppl. 3: 15–20Google Scholar
  20. 20.
    McIntyre RS, Konarski JZ, Keck PE. Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. In: McElroy SL, Allison DB, Bray GA, editors. Obesity and mental disorders. New York: Taylor & Francis, 2005: 307–52Google Scholar
  21. 21.
    McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Expert Opin Drug Saf 2006 Jul; 5(4): 523–37PubMedCrossRefGoogle Scholar
  22. 22.
    McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006 Jan; 5(1): 157–68PubMedCrossRefGoogle Scholar
  23. 23.
    van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia 1965 Jun 1; 8(1): 67–78PubMedCrossRefGoogle Scholar
  24. 24.
    van Pragg H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 1963 May; 8: 466–75CrossRefGoogle Scholar
  25. 25.
    Van Praag HM, Leijnse B. The xylose metabolism in depressed patients and its alterations under the influence of antidepressive hydrazines. Clinica Chimica Acta 1965; 11: 13–23CrossRefGoogle Scholar
  26. 26.
    Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 1988 Oct; 22(10): 755–9PubMedGoogle Scholar
  27. 27.
    Davidson J, Turnbull CD. The effects of isocarboxazid on blood pressure and pulse. J Clin Psychopharmacol 1986 Jun; 6(3): 139–43PubMedCrossRefGoogle Scholar
  28. 28.
    Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharmacol 1984 Oct; 4(5): 270–8Google Scholar
  29. 29.
    Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: introduction. J Affect Disord 2009 Oct; 117 Suppl. 1: S1–2PubMedCrossRefGoogle Scholar
  30. 30.
    Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995 Jan 11; 33(1): 1–9PubMedCrossRefGoogle Scholar
  31. 31.
    Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002 Mar; 47(2): 174–80PubMedGoogle Scholar
  32. 32.
    Vaz-Serra A, Figueira ML, Firmino H, et al. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 Suppl. 1: S38–49PubMedCrossRefGoogle Scholar
  33. 33.
    Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992; 106 Suppl. : S98–101CrossRefGoogle Scholar
  34. 34.
    Moll E, Neumann N, Schmid-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994; 17 Suppl. 1: S74–87PubMedCrossRefGoogle Scholar
  35. 35.
    Ghaeli P, Shahsavand E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004 Aug; 24(4): 386–8PubMedCrossRefGoogle Scholar
  36. 36.
    Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997 May; 59(3): 241–50PubMedGoogle Scholar
  37. 37.
    Moosa MY, Panz VR, Jeenah FY, et al. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003 Dec; 23(6): 549–52PubMedCrossRefGoogle Scholar
  38. 38.
    Yeragani VK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychiatry Res 1990 May; 32(2): 207–9PubMedCrossRefGoogle Scholar
  39. 39.
    Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000 Jul; 23(1): 13–9PubMedCrossRefGoogle Scholar
  40. 40.
    Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005 Nov; 25(11): 1048–53PubMedCrossRefGoogle Scholar
  41. 41.
    Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973 Nov; 123(576): 501–7PubMedCrossRefGoogle Scholar
  42. 42.
    Sansone RA, Wiederman MW, Shrader JA. Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. J Clin Psychopharmacol 2000 Apr; 20(2): 272–4PubMedCrossRefGoogle Scholar
  43. 43.
    Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 2004 Oct; 24(5): 527–31PubMedCrossRefGoogle Scholar
  44. 44.
    Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988 Dec; 26(3): 265–71PubMedCrossRefGoogle Scholar
  45. 45.
    Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984 Oct; 7(2): 133–8PubMedCrossRefGoogle Scholar
  46. 46.
    Frank E, Kupfer DJ, Buhari A, et al. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992 Sep; 26(1): 65–72PubMedCrossRefGoogle Scholar
  47. 47.
    Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979 Nov; 41(7): 535–44PubMedGoogle Scholar
  48. 48.
    Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987 Jan; 48(1): 27–8PubMedGoogle Scholar
  49. 49.
    Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001 Apr; 62(4): 256–60PubMedCrossRefGoogle Scholar
  50. 50.
    Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun;14(3): 170–9PubMedCrossRefGoogle Scholar
  51. 51.
    Perry PJ, Garvey MJ, Dunner DL, et al. A report of trazodone-associated laboratory abnormalities. Ther Drug Monit 1990 Nov; 12(6): 517–9PubMedCrossRefGoogle Scholar
  52. 52.
    Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997 Feb; 21(2): 97–102PubMedCrossRefGoogle Scholar
  53. 53.
    O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan; 11(1): 105–10PubMedCrossRefGoogle Scholar
  54. 54.
    Potter van Loon BJ, Radder JK, Frolich M, et al. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S55–61Google Scholar
  55. 55.
    Gray DS, Fujioka K, Devine W, et al. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S67–72PubMedGoogle Scholar
  56. 56.
    Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006 Dec; 67(12): 1856–61PubMedCrossRefGoogle Scholar
  57. 57.
    Chen YC, Shen YC, Hung YJ, et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007 Nov; 103(1–3): 257–61PubMedCrossRefGoogle Scholar
  58. 58.
    Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003 Dec; 64(12): 1455–9PubMedCrossRefGoogle Scholar
  59. 59.
    Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246(1): 1–6PubMedCrossRefGoogle Scholar
  60. 60.
    Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005 Sep; 21(3): 129–37PubMedCrossRefGoogle Scholar
  61. 61.
    Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec; 20(6): 645–52PubMedCrossRefGoogle Scholar
  62. 62.
    Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000 Nov; 61(11): 863–7PubMedCrossRefGoogle Scholar
  63. 63.
    Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998 Mar; 13(2): 63–73PubMedCrossRefGoogle Scholar
  64. 64.
    Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996 Jul; 4(4): 391–6PubMedCrossRefGoogle Scholar
  65. 65.
    Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug; 156(8): 1170–6PubMedGoogle Scholar
  66. 66.
    Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001 Apr; 64(1): 43–51PubMedCrossRefGoogle Scholar
  67. 67.
    Seo HJ, Jung YE, Woo YS, et al. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psychopharmacol 2009 Mar; 24(2): 135–43PubMedCrossRefGoogle Scholar
  68. 68.
    Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65(9): 1190–6PubMedCrossRefGoogle Scholar
  69. 69.
    Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005 Apr; 17(2): 65–9PubMedCrossRefGoogle Scholar
  70. 70.
    Gulseren L, Gulseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005 Mar; 36(2): 159–65PubMedCrossRefGoogle Scholar
  71. 71.
    Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 Sep; 250(3): 219–24PubMedCrossRefGoogle Scholar
  72. 72.
    Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004 Jun; 65(6): 766–71PubMedCrossRefGoogle Scholar
  73. 73.
    Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20(3): 131–7PubMedCrossRefGoogle Scholar
  74. 74.
    Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003 May 14; 4: 7PubMedCrossRefGoogle Scholar
  75. 75.
    Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002 Jul; 43(4): 310–6PubMedCrossRefGoogle Scholar
  76. 76.
    Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007 Apr; 41(3–4): 344–50PubMedCrossRefGoogle Scholar
  77. 77.
    Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007 Jan; 30(1): 21–6PubMedCrossRefGoogle Scholar
  78. 78.
    Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007 Sep; 8(6): 503–13PubMedCrossRefGoogle Scholar
  79. 79.
    Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 Sep; 23(5): 243–53PubMedCrossRefGoogle Scholar
  80. 80.
    Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63(4): 308–15PubMedCrossRefGoogle Scholar
  81. 81.
    Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007 Nov; 68(11): 1663–72PubMedCrossRefGoogle Scholar
  82. 82.
    Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 Aug; 68(8): 1246–56PubMedCrossRefGoogle Scholar
  83. 83.
    Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007 Dec 15; 62(12): 1371–9PubMedCrossRefGoogle Scholar
  84. 84.
    Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (1): PCC.08m00746Google Scholar
  85. 85.
    Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14(6): 457–70PubMedCrossRefGoogle Scholar
  86. 86.
    Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66(2): 238–47PubMedCrossRefGoogle Scholar
  87. 87.
    Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006 Sep; 7(5): 373–85PubMedCrossRefGoogle Scholar
  88. 88.
    Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24(1): 41–52PubMedCrossRefGoogle Scholar
  89. 89.
    Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006 Jan; 29(1): 170PubMedCrossRefGoogle Scholar
  90. 90.
    Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003 Aug; 64(8): 883–9PubMedCrossRefGoogle Scholar
  91. 91.
    Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–4PubMedCrossRefGoogle Scholar
  92. 92.
    Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 Jan; 60(1): 45–9PubMedCrossRefGoogle Scholar
  93. 93.
    Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas) 2009; 45(10): 778–84Google Scholar
  94. 94.
    Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes 2010 Feb; 118(2): 98–100PubMedCrossRefGoogle Scholar
  95. 95.
    Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 797PubMedCrossRefGoogle Scholar
  96. 96.
    Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001 Sep; 9(9): 544–51PubMedCrossRefGoogle Scholar
  97. 97.
    Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002 Oct; 10(10): 1049–56Google Scholar
  98. 98.
    Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58PubMedCrossRefGoogle Scholar
  99. 99.
    Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32PubMedCrossRefGoogle Scholar
  100. 100.
    Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008 Jun; 28(3): 302–7PubMedCrossRefGoogle Scholar
  101. 101.
    Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007 Mar; 30(3): 459–66PubMedCrossRefGoogle Scholar
  102. 102.
    Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001 Mar; 13(1): 31–41PubMedGoogle Scholar
  103. 103.
    Lustman PJ, Clouse RE. Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 2002 Oct; 53(4): 917–24PubMedCrossRefGoogle Scholar
  104. 104.
    Lustman PJ, Clouse RE. Depression in diabetes: the chicken or the egg? Psychosom Med 2007 May; 69(4): 297–9PubMedCrossRefGoogle Scholar
  105. 105.
    McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005 Apr; 17(2): 83–93PubMedCrossRefGoogle Scholar
  106. 106.
    Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan; 37(1): 68–73PubMedCrossRefGoogle Scholar
  107. 107.
    Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1946; 102: 108–10Google Scholar
  108. 108.
    Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989 Mar 4; 1(8636): 495PubMedCrossRefGoogle Scholar
  109. 109.
    Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009 May; 166(5): 591–8PubMedCrossRefGoogle Scholar
  110. 110.
    Raskin JWFWJFSCCJW. Duloxetine does not affect glycemic control or lipid profiles in patients with diabetic neuropathic pain. Presented at the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)Google Scholar
  111. 111.
    Othmer E, Othmer SC, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 153–6PubMedGoogle Scholar
  112. 112.
    Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000 Oct; 49(10): 1255–60PubMedCrossRefGoogle Scholar
  113. 113.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421Google Scholar
  114. 114.
    Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998 Oct; 19 Suppl. M: M8–14PubMedGoogle Scholar
  115. 115.
    Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994 Feb 5; 308(6925): 367–72PubMedCrossRefGoogle Scholar
  116. 116.
    Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998 Feb 26; 81(4A): 7B–12BPubMedCrossRefGoogle Scholar
  117. 117.
    Canadian Pharmacist Association. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacist Association, 2007Google Scholar
  118. 118.
    Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62(2): 190–8PubMedCrossRefGoogle Scholar
  119. 119.
    Visser M, Seidell JC, Koppeschaar HP, et al. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994 Mar; 2(2): 152–9PubMedCrossRefGoogle Scholar
  120. 120.
    Fisar Z, Anders M, Tvrzicka E, et al. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 2005 Jun; 24(2): 221–36PubMedGoogle Scholar
  121. 121.
    Masuda Y, Ohnuma S, Sugiyama T. Relationship between antidepressants and glycolipids in the forced swimming test in mice. Methods Find Exp Clin Pharmacol 2000 Nov; 22(9): 667–70PubMedCrossRefGoogle Scholar
  122. 122.
    Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006 Sep; 68(5): 645–50PubMedCrossRefGoogle Scholar
  123. 123.
    Frasure-Smith N, Lesperance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006 Oct; 51(12): 730–7PubMedGoogle Scholar
  124. 124.
    Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998 Jan; 155(1): 4–11PubMedGoogle Scholar
  125. 125.
    Dobbels F, De GS, Vanhees L, et al. Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease. Eur J Cardiovasc Nurs 2002 Feb; 1(1): 45–55PubMedCrossRefGoogle Scholar
  126. 126.
    Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002 Dec; 5(4): 333–43PubMedCrossRefGoogle Scholar
  127. 127.
    Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998 Jul; 55(7): 580–92PubMedCrossRefGoogle Scholar
  128. 128.
    Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004 Mar; 25(6): 492–9PubMedCrossRefGoogle Scholar
  129. 129.
    Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses 2002 Nov; 59(5): 537–51PubMedCrossRefGoogle Scholar
  130. 130.
    Scalco AZ, Scalco MZ, Azul JB, et al. Hypertension and depression. Clinics 2005 Jun; 60(3): 241–50PubMedCrossRefGoogle Scholar
  131. 131.
    Davidson K, Jonas BS, Dixon KE, et al. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med 2000 May 22; 160(10): 1495–500PubMedCrossRefGoogle Scholar
  132. 132.
    Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006 Feb; 9(1): 29–40PubMedCrossRefGoogle Scholar
  133. 133.
    Wohlreich MM, Perahia DG, Acharya N, et al. Duloxetine hepatic effects: 2006 review. Austria European Congress of Neuropsychopharmacology; 2007 Oct 13; ViennaGoogle Scholar
  134. 134.
    Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005 Feb; 66(2): 253–9PubMedCrossRefGoogle Scholar
  135. 135.
    Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991 Apr; 148(4): 512–6PubMedGoogle Scholar
  136. 136.
    Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S–58SPubMedGoogle Scholar
  137. 137.
    Botella-Carretero JI, Escobar-Morreale HF, Martin I, et al. Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm Metab Res 2004 Mar; 36(3): 178–82PubMedCrossRefGoogle Scholar
  138. 138.
    Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996 Mar; 57(3): 99–104PubMedGoogle Scholar
  139. 139.
    McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004 May; 65(5): 634–51, quizPubMedCrossRefGoogle Scholar
  140. 140.
    Pine DS, Goldstein RB, Wolk S, et al. The association between childhood depression and adulthood body mass index. Pediatrics 2001 May; 107(5): 1049–56PubMedCrossRefGoogle Scholar
  141. 141.
    McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004; 19(6): 369–86PubMedCrossRefGoogle Scholar
  142. 142.
    Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 Mar 24; 322(7288): 716–20PubMedCrossRefGoogle Scholar
  143. 143.
    Weber-Hamann B, Hentschel F, Kniest A, et al. Hyper-cortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002 Mar; 64(2): 274–7PubMedGoogle Scholar
  144. 144.
    Hach I, Ruhl UE, Klotsche J, et al. Associations between waist circumference and depressive disorders. J Affect Disord 2006 Jun; 92(2–3): 305–8PubMedCrossRefGoogle Scholar
  145. 145.
    McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274–80PubMedGoogle Scholar
  146. 146.
    Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41Google Scholar
  147. 147.
    Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. Can J Psychiatry 1993 Feb; 38(1): 19–22PubMedGoogle Scholar
  148. 148.
    Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352–9PubMedCrossRefGoogle Scholar
  149. 149.
    Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999 Jan; 14(1): 19–28PubMedCrossRefGoogle Scholar
  150. 150.
    Frank E, Kupfer DJ, Bulik CM, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990 Nov; 20(3): 165–72PubMedCrossRefGoogle Scholar
  151. 151.
    Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999 Jan; 60(1): 22–8PubMedCrossRefGoogle Scholar
  152. 152.
    Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988 Oct; 8(5): 323–30PubMedCrossRefGoogle Scholar
  153. 153.
    Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994 Mar; 30(3): 193–207PubMedCrossRefGoogle Scholar
  154. 154.
    Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003 May; 37(3): 193–220PubMedCrossRefGoogle Scholar
  155. 155.
    Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007 Mar 30; 31(2): 370–2PubMedCrossRefGoogle Scholar
  156. 156.
    Kendall-Tackett KA. Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: the role of depression, hostility, and sleep disturbance. Trauma Violence Abuse 2007 Apr; 8(2): 117–26PubMedCrossRefGoogle Scholar
  157. 157.
    Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002 Oct; 53(4): 873–6PubMedCrossRefGoogle Scholar
  158. 158.
    Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999 Jul; 4(4): 317–27PubMedCrossRefGoogle Scholar
  159. 159.
    Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 May; 26(5): 643–52PubMedCrossRefGoogle Scholar
  160. 160.
    Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004 Dec 1; 56(11): 819–24PubMedCrossRefGoogle Scholar
  161. 161.
    Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365–70PubMedCrossRefGoogle Scholar
  162. 162.
    McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res 2002 Oct; 53(4): 883–90PubMedCrossRefGoogle Scholar
  163. 163.
    Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23CrossRefGoogle Scholar
  164. 164.
    McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med 1993 Sep 27; 153(18): 2093–101PubMedCrossRefGoogle Scholar
  165. 165.
    McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003 Aug 1; 54(3): 200–7PubMedCrossRefGoogle Scholar
  166. 166.
    Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993 May; 47(2): 163–73PubMedCrossRefGoogle Scholar
  167. 167.
    Belanoff JK, Kalehzan M, Sund B, et al. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001 Oct; 158(10): 1612–6PubMedCrossRefGoogle Scholar
  168. 168.
    Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006 Aug 1; 60(3): 275–81PubMedCrossRefGoogle Scholar
  169. 169.
    Rebuffe-Scrive M, Walsh UA, McEwen B, et al. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992 Sep; 52(3): 583–90PubMedCrossRefGoogle Scholar
  170. 170.
    Gil K, Radzillowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome: results of the SOPKARD Project. Kardiol Pol 2006 May; 64(5): 464–9PubMedGoogle Scholar
  171. 171.
    Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004 May; 66(3): 316–22PubMedCrossRefGoogle Scholar
  172. 172.
    Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008 Jan; 70(1): 40–8PubMedCrossRefGoogle Scholar
  173. 173.
    Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002 Apr; 68(2–3): 167–81PubMedCrossRefGoogle Scholar
  174. 174.
    Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep; 58(9): 844–50PubMedCrossRefGoogle Scholar
  175. 175.
    Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders: VII. Comorbidity. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 77S–90SPubMedGoogle Scholar
  176. 176.
    Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 Aug 14; 288(6): 701–9PubMedCrossRefGoogle Scholar
  177. 177.
    American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S11–4CrossRefGoogle Scholar
  178. 178.
    McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 2009 Jun; 70(6): e17PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Roger S. McIntyre
    • 1
    • 2
    • 3
    • 4
  • Ka Young Park
    • 5
  • Candy W. Y. Law
    • 3
  • Farah Sultan
    • 3
  • Amanda Adams
    • 3
  • Maria Teresa Lourenco
    • 3
  • Aaron K. S. Lo
    • 3
  • Joanna K. Soczynska
    • 3
    • 4
  • Hanna Woldeyohannes
    • 3
  • Mohammad Alsuwaidan
    • 1
    • 3
  • Jinju Yoon
    • 3
  • Sidney H. Kennedy
    • 1
    • 3
    • 4
  1. 1.Department of PsychiatryUniversity of TorontoTorontoCanada
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada
  3. 3.Mood Disorders Psychopharmacology UnitUniversity Health NetworkTorontoCanada
  4. 4.Institute of Medical ScienceUniversity of TorontoTorontoCanada
  5. 5.Department of Family and Community MedicineUniversity of TorontoOntarioCanada

Personalised recommendations